2018版转移性前列腺癌诊治中国专家共识

Chinese experts consensus on the treatment of metastatic prostate cancer 2018 edition

前列腺癌在中国的发病率逐年升高，大多数前列腺癌患者在初诊时就已经出现转移。随机对照临床试验结果证实，具有高危因素的患者早期接受阿比特龙或多西他赛联合内分泌治疗其总体生存时间能获得更明显的受益，转移性去势抵抗性前列腺癌药物治疗选择包括多西他赛、阿比特龙或恩杂鲁胺等多种可明显延长生存时间的药物，其中多西他赛和阿比特龙积累了较多的国人应用经验。如何正确地应用目前的治疗手段，为中国转移性前列腺癌患者制定最佳的诊疗方案是摆在临床医师面前的重要问题。中国抗癌协会泌尿男生殖系肿瘤专业委员会组织专家撰写了本共识，希望帮助临床医师做出合理的临床决策，延长患者生存时间和提高生活质量。

The prevalence of prostate cancer has shown a marked increase in China. Most patients are presented with metastasis at diagnosis. It has been proven by clinical trials that besides androgen deprivation therapy, Abiraterone and docetaxel can improve the overall survival of metastatic hormone sensitive prostate cancer patients with high risks. For metastatic castration-resistant prostate cancer treatment, docetaxel, abiraterone and enzalutamide, etc., have demonstrated significant overall survival benefit. Among them, docetaxel and abiraterone have accumulated adequate experience in Chinese patients. Therefore, it is quite important for Chinese physicians to make reasonable clinical decisions based on these treatment regimes. In order to improve patients＇ survival and life quality, Chinese Anticancer Association Genitourinary Oncology Committee composed this expert consensus to help physicians to make reasonable decisions.